Baikal Skullcap for Health & Longevity - Quick Reference Sheet

Baikal Skullcap for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A long-used East Asian root whose yellow pigments block two inflammatory routes at once. The clearest human benefit is symptom relief in knee and hip arthritis; thinner evidence covers lower blood fats, reduced gum inflammation, and better mood under stress. Liver injury and lung inflammation shape any decision. The signal is real but narrow. (Full Review)

Protocol

Standard practitioner protocol
250–500 mg/day
Root extract standardised to 85–90% baicalin, taken with food
Best time of day
Morning and evening
With meals; food raises flavone peak concentrations roughly 1.6-fold
Single versus split dosing
Split into two doses
Peak levels arrive within one to two hours; split-dose joint trials reported the cleanest tolerability
Time to effect
Joint pain
Within 1 week
Continued through 90 days
Gum inflammation
14–21 days
From a root-extract toothpaste
Mood
7–15 days
Measured in stressed adults

Benefits

Contraindications
  • Active liver disease, cirrhosis of Child-Pugh Class B or C, or baseline alanine aminotransferase above twice the upper limit of normal
  • Previously documented herb-induced or drug-induced liver injury from any agent
  • Pregnant or breastfeeding women
  • Solid-organ transplant recipients maintained on calcineurin inhibitors (cyclosporine, tacrolimus)
  • Interstitial lung disease or prior hypersensitivity pneumonitis of any cause
  • Within 14 days of scheduled surgery or a spinal or epidural procedure
Key Interactions
  • Statins and other OATP1B1 substrates (rosuvastatin, pravastatin, atorvastatin, repaglinide)
  • CYP3A4 substrates with narrow margins (everolimus, sirolimus, some oral anticancer agents)
  • Glucose-lowering drugs (metformin, sulfonylureas such as glipizide, insulin)
  • Other hepatotoxic agents (acetaminophen above 2 g/day, methotrexate, isoniazid, high-dose niacin, kava, green tea extract)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)
  • Over-the-counter medications (ibuprofen, naproxen, acetaminophen, antacids, proton pump inhibitors)
  • Supplement interactions (berberine, milk thistle, quercetin)
  • Supplements with additive anti-inflammatory or glucose-lowering effects (curcumin, boswellia, fish oil, cutch tree extract, berberine, cinnamon)
  • Other intervention interactions (broad-spectrum antibiotics, ethanol)

Risk & Side Effects

  • High: Drug-induced liver injury
  • Medium: Hypersensitivity pneumonitis; gastrointestinal intolerance
  • Low: Reduced exposure to transporter-dependent drugs; additive blood-glucose lowering
  • Speculative: Sedation and additive central nervous system depression; increased bleeding tendency

Monitoring

Marker Target Why
Alanine aminotransferase < 25 U/L (men), < 20 U/L (women) Earliest and most sensitive signal of liver-cell injury
Alkaline phosphatase 50–100 U/L Detects the cholestatic component of the mixed injury pattern
Gamma-glutamyl transferase < 20 U/L (men), < 15 U/L (women) Confirms that a raised alkaline phosphatase is liver rather than bone
Total bilirubin 0.3–1.0 mg/dL Marks injury severe enough to impair hepatic clearance
Eosinophil percentage < 3% of white cells Supports an immune-mediated mechanism when enzymes rise
High-sensitivity C-reactive protein < 1.0 mg/L Tracks the anti-inflammatory effect the intervention is taken for
Fasting glucose 75–90 mg/dL Detects additive lowering when combined with glucose-lowering drugs
Low-density lipoprotein cholesterol Target set by the prescribing clinician; track change from the individual's own pre-supplement value Detects loss of statin effect from transporter interaction

Cadence: Liver panel at baseline, 8 weeks, and the end of each 12-week course, then before restarting after any break; lipid panel at 8 weeks where a statin is co-prescribed; fasting glucose weekly for the first month where glucose-lowering drugs are in use

Qualitative Assessment

  • Joint pain and morning stiffness, scored the same way each week
  • Energy and daytime alertness, which sedation would blunt
  • Sleep onset latency and perceived sleep quality
  • Perceived stress, irritability, and anxiety
  • Gum bleeding on brushing
  • Appetite, nausea, and stool consistency
  • Any new dry cough or breathlessness on exertion
  • Urine colour, skin or eye yellowing, and itch